Skip to main content

Anti-fibrotic Drugs Targeting Synthesis of Type 1 Collagen

Tech ID:
10-042, 12-047, 17-024, 19-034, and 20-047
Principal Investigator:
Branko Stefanovi
Licensing Manager:

Fibrosis affects 45% of the population in the USA. It is characterized by excessive synthesis of type 1 collagen and scarring of various organs. This leads to organ insufficiency and death. The process is chronic and progressive and there are no approved drugs that can inhibit collagen synthesis. Aspects of the regulation of type 1 collagen production have been delineated and a drug screening procedure based on disruption of the regulatory pathway has been devised. Using this screening procedure a library of chemicals compounds has been screened and nine compounds that can inhibit collagen synthesis in cultured cells between 50-90% have been found.

This is a completely novel approach to finding antifibrotic drugs. If these compounds prove to be effective in humans, they will be the first chemicals that can directly inhibit collagen production. Since there is no cure for fibrosis, they may represent the first specific antifibrotic drugs.

This technology consists of two novel assay systems and three potential antifibrosis drugs.